We are developing #Oncojans, a promising new class of drug-loaded particles, designed to precisely target and gain entry to cancer cells. In the tumours, they slowly release drugs at the point of need whilst sparing healthy tissue. Early preclinical studies for #BMT101, our lead ovarian cancer candidate, compared to the clinical standard of care, Taxol®, have shown very encouraging results including over 10-fold increases in drug concentration in tumours, 65-fold reductions in tumour burden, 4-fold increases in survival and loss of toxicity. #BMT101 and future engineered #Oncojans could be transformational in the treatment of cancer patients.